Journal of Urban Health

, Volume 77, Issue 3, pp 425–437

Involving women in HIV vaccine efficacy trials: Lessons learned from a vaccine prepared ness study in New York City

  • Pamela Brown-Peterside
  • Mary Ann Chiasson
  • Leigh Ren
  • Beryla Koblin
Original Articles: Substance Use and HIV Prevention

Abstract

This paper identifies the recruitment strategies and human immunodeficiency virus (HIV) risk behaviors of at-risk women in an HIV vaccine preparredness study in New York City, assesses how these behaviors changed over time, and draws implications for women's involvement in HIV vaccine efficacy trials. Noninjecting HIV-1 ngative women (N=89) were recruited into an HIV vaccine preparedness study. An observational cohort study design was used. Women were recruited from clinics and community-based organizations (40%), through other study participants (24%), through newspaper advertisements (20%), and through street outreach (16%). Most women who refused (72%) also came from clinics and agencies. Retention after 12 months was 67%; after 18 months, it was 62%. The proportion of women reporting unprotected vaginal sex in the previous 3 months was 85% at baseline and declined to 70% after 12 months (P<.05). There have been no seroconversions detected. Recruitment efforts to include at-risk women in HIV vaccine efficacytrials must be diverse and actively involve community agencies. Successfully retaining these cohorts over time and detecting a high enough HIV seroincidence rate present ongoing challenges that will need to be addressed to ensure women's involvement in future trials in the US

Key words

Efficacy Trials HIV Vaccine Preparedness Study Women 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wortley PM, Fleming PL. AIDS in women in the United States.JAMA. 1997;278(11):911–916.CrossRefPubMedGoogle Scholar
  2. 2.
    Graham BS, Wright PF. Candidate AIDS vaccines.N Engl J Med. 1995;333:1331–1339.PubMedGoogle Scholar
  3. 3.
    Bloom BR. A perspective on AIDS vaccines.Science. 1996;272:1888–1890.PubMedGoogle Scholar
  4. 4.
    Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States.AIDS. 1998;12:785–793.CrossRefPubMedGoogle Scholar
  5. 5.
    Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:30–35.PubMedGoogle Scholar
  6. 6.
    Koblin BA, Avrett S, Taylor PE, Stevens CE. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE.J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15: 165–171.PubMedGoogle Scholar
  7. 7.
    Hunt JR, White E. Retaining and tracking cohort study members.Epidemiol Rev. 1998; 20(1):57–70.PubMedGoogle Scholar
  8. 8.
    Mausner JS, Bahn AK.Epidemiology: An Introductory Text. Philadelphia, PA: W. B. Saunders and Company; 1985.Google Scholar
  9. 9.
    Worth D. Women at high risk of HIV infection: behavioral, prevention and intervention aspects. In: Ostrow DG, ed.Behavioral Aspects of AIDS. New York: Plenum; 1990: 101–119.Google Scholar
  10. 10.
    Wright J. Asking for community assistance to prepare for large HIV vaccine trials in San Francisco. Paper presented at:Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland. Abstract 24215.Google Scholar
  11. 11.
    Auerbach JD, Figert AE. Women's health research: public policy and sociology.J Health Soc Behav. 1995;(spec. no.); 115–131.Google Scholar
  12. 12.
    El-Bassel N, Schilling RF. Fifteen-month follow-up of women methadone patients taught skills to reduce heterosexual HIV transmission.Public Health Rep. 1992;107: 500–504.PubMedGoogle Scholar
  13. 13.
    El-Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS.JAMA. 1992;267(7):954–957.CrossRefPubMedGoogle Scholar
  14. 14.
    Brown-Peterside P, Smith C, Affleck P, Doherty-Iddings P, Harrison C, Clark C. Enabling women to Participate in HIV vaccine efficacy trials: lessons learned from a US vaccine preparedness study. Paper presented at:Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland. Abstract 33215.Google Scholar
  15. 15.
    Osborn JE. The rocky road to an AIDS vaccine.J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:26–29.PubMedGoogle Scholar
  16. 16.
    Seage GE III, Metzger D, Holte S, Buchbinder S, Koblin B, Celum C. Feasibility of conducting HIV-1 vaccine trials in the United States: recruitment, retention and HIV-1 seroincidence from the HIV Network for Prevention Trials (HIVNET) Vaccine Preparedness Study (VPS). Paper presented at:Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland. Abstract 43543.Google Scholar
  17. 17.
    Exner TM, Seal DW, Ehrhardt AA. A review of HIV interventions for at-risk women.AIDS. 1997;2(1):93–124.Google Scholar
  18. 18.
    Stein ZA. HIV prevention: the need for methods women can use.Am J Public Health. 1990;80:460–462.PubMedGoogle Scholar
  19. 19.
    Birmingham K. HIV Vaccines—and the winner is ...Nat Med. 1998;4(7):753.PubMedGoogle Scholar

Copyright information

© The New York Academy of Medicine 2000

Authors and Affiliations

  • Pamela Brown-Peterside
    • 1
  • Mary Ann Chiasson
    • 1
  • Leigh Ren
    • 1
  • Beryla Koblin
    • 1
  1. 1.Wolf Szmuness Laboratory of EpidemiologyThe New York Blood CenterNew YorkUSA
  2. 2.Wolf Szumness Laboratory of EpidemiologyThe New York Blood CenterBronxUSA

Personalised recommendations